文献速递其他结缔组织病系统性红斑狼疮

造血干细胞移植、嵌合抗原受体T细胞及其他细胞疗法作为严重硬皮病和其他自身免疫病长期改善的进阶手段

Hematopoietic stem cell transplant, chimeric antigen receptor T-cells, and other cellular therapies as stepping stones toward long-term improvement in severe scleroderma and other autoimmune diseases.
PubMed 文献 · Semin Arthritis Rheum · 2025-02-25

临床前模型显示,大剂量免疫抑制预处理后的造血干细胞移植(HSCT)可逆转器官损伤并改变自身免疫病(AID)病程,其原理基于免疫系统重置。三项比较自体HSCT与标准环磷酰胺(CY)的随机试验显示,移植后12-54个月严重系统性硬化症(SSc)显著改善,Meta分析显示HSCT全因死亡相对风险为0.5。近期,CY/氟达拉滨预处理后CD19嵌合抗原受体(CAR)T细胞输注在多种AID中观察到临床改善,随访4-29个月出现主要疾病缓解和完全B细胞重建,副作用轻微。

要点

  • 三项随机试验中自体HSCT较标准CY在移植后12-54个月显著改善严重SSc。
  • Meta分析显示HSCT全因死亡相对风险为0.5(对照CY)。
  • CY/氟达拉滨后CD19 CAR-T输注随访4-29个月见主要疾病缓解和完全B细胞重建,副作用轻微。

核心结论

  • 自体HSCT在严重SSc中较标准CY显著改善且全因死亡相对风险为0.5。
  • CD19 CAR-T细胞输注在多种AID中随访4-29个月观察到主要疾病缓解和完全B细胞重建,副作用轻微。
  • MSC给药后已有临床改善报告,但随访仍短暂。
  • 自体HSCT因随访更长且许多患者临床改善并数十年无需DMARDs生存,与患者共同决策可能更容易。

研究设计与样本

  • 临床前模型研究及三项比较自体HSCT与标准CY的随机试验的Meta分析。
  • CY/氟达拉滨预处理后CD19 CAR-T细胞输注的临床观察,随访4-29个月。
  • 工业界和学术中心正在开发CAR-NK、现货型CAR-T、嵌合自身抗体受体(CAAR-T)和间充质基质细胞(MSC)等细胞产品用于AID治疗。

主要发现

  • 三项随机试验中自体HSCT较标准CY在移植后12-54个月显著改善SSc。
  • Meta分析显示HSCT全因死亡相对风险为0.5(对照CY)。
  • CD19 CAR-T输注后随访4-29个月观察到主要疾病缓解和完全B细胞重建,副作用轻微。
  • MSC给药后已有临床改善报告,但随访仍短暂。

临床怎么用

  • 自体HSCT因随访更长且许多患者临床改善并数十年无需DMARDs生存,与患者共同决策可能更容易。

局限性

  • MSC给药后临床改善报告的随访仍短暂。
  • 与CAR-T试验一样,MSC的随访仍短暂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Preclinical models of inherited and induced autoimmune diseases (AIDs) have shown that hematopoietic stem cell transplantation (HSCT) following high-dose immunosuppressive conditioning could reverse organ damage and alter the course of AIDs. The rationale for both autologous and allogeneic HSCT has been based upon a reset of the immune system. Clinical application of HSCT was initially focused on severe systemic sclerosis (SSc) and three randomized trials comparing autologous HSCT with standard cyclophosphamide (CY) demonstrated significant improvement in SSc measured 12-54 months after transplant. Meta-analysis of the three trials showed the relative risk of all-cause mortality after HSCT was 0.5 compared to CY. More recently, clinical improvements in several AIDs have been reported with CY/fludarabine preparation followed by CD19 chimeric antigen receptor (CAR) T-cell infusion. With follow-up of 4-29 months, major disease responses and full B-cell reconstitution have been observed while side effects have been modest. Industry and academic centers are active in developing these and other cellular products for AID treatments including CAR-NK, off the shelf CAR-Ts, chimeric autoantibody receptor (CAAR-Ts), and mesenchymal stromal cells (MSCs). Clinical improvements after MSC administration have been reported, but as with the CAR-T trials, follow-up is still brief. Shared decision making with patients considering cellular therapy is perhaps easier for autologous HSCT since we have longer follow-up with many patients clinically improved and surviving off DMARDS for decades. Such individuals understandably view themselves as cured. Thus, the interest in the evolving role of cellular therapies in long-term improvement in severe AIDs.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Sullivan KM. Hematopoietic stem cell transplant, chimeric antigen receptor T-cells, and other cellular therapies as stepping stones toward long-term improvement in severe scleroderma and other autoimmune diseases. Semin Arthritis Rheum. 2025. PMID: 40058994. doi:10.1016/j.semarthrit.2025.152676

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。